>> Targeting EGF-1 might be an added benefit but it also reduces MTD and reduces HER-2 inhibition.
We are not talking about single agent here. Even if we do, oncology has been obsessed with MTD, resulting so many small companies with unnecessarily high so-called MTD - it is over rated for target agents especially in combination with similar agents, mechanism is more important than so-called MTD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.